Back to top

gene-editing: Archive

Zacks Equity Research

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

VRTXPositive Net Change ANIPPositive Net Change FATEPositive Net Change EDITPositive Net Change

Zacks Equity Research

Agilent Expands LSAG Segment: How Should You Approach the Stock?

A's expanding LSAG portfolio may bode well for the stock, despite macroeconomic risks and stretched valuation.

ITRIPositive Net Change APositive Net Change TERPositive Net Change FTVPositive Net Change